IL221741A - Alpha stabilized galactosidase and its uses - Google Patents

Alpha stabilized galactosidase and its uses

Info

Publication number
IL221741A
IL221741A IL221741A IL22174112A IL221741A IL 221741 A IL221741 A IL 221741A IL 221741 A IL221741 A IL 221741A IL 22174112 A IL22174112 A IL 22174112A IL 221741 A IL221741 A IL 221741A
Authority
IL
Israel
Prior art keywords
galactosidase
stabilized alpha
stabilized
alpha
Prior art date
Application number
IL221741A
Other languages
English (en)
Hebrew (he)
Inventor
Shaaltiel Yoseph
Shulman Avidor
Azulay Yaniv
Ruderfer Ilya
Ben-Moshe Tehila
Shekhter Talia
Kizhner Tali
Original Assignee
Shaaltiel Yoseph
Shulman Avidor
Protalix Ltd
Azulay Yaniv
Ruderfer Ilya
Tehila Ben Moshe
Shekhter Talia
Kizhner Tali
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2010/000956 external-priority patent/WO2011061736A1/en
Application filed by Shaaltiel Yoseph, Shulman Avidor, Protalix Ltd, Azulay Yaniv, Ruderfer Ilya, Tehila Ben Moshe, Shekhter Talia, Kizhner Tali filed Critical Shaaltiel Yoseph
Publication of IL221741A publication Critical patent/IL221741A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
IL221741A 2010-03-02 2012-09-02 Alpha stabilized galactosidase and its uses IL221741A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30948710P 2010-03-02 2010-03-02
PCT/IL2010/000956 WO2011061736A1 (en) 2009-11-17 2010-11-17 Alkaline alpha galactosidase for the treatment of fabry disease
US201161434499P 2011-01-20 2011-01-20
US201161434503P 2011-01-20 2011-01-20
PCT/IL2011/000209 WO2011107990A1 (en) 2010-03-02 2011-03-02 Stabilized alpha-galactosidase and uses thereof

Publications (1)

Publication Number Publication Date
IL221741A true IL221741A (en) 2017-07-31

Family

ID=44121635

Family Applications (2)

Application Number Title Priority Date Filing Date
IL221741A IL221741A (en) 2010-03-02 2012-09-02 Alpha stabilized galactosidase and its uses
IL253249A IL253249B (en) 2010-03-02 2017-06-29 Stabilized alpha-galactosidase and its uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL253249A IL253249B (en) 2010-03-02 2017-06-29 Stabilized alpha-galactosidase and its uses

Country Status (23)

Country Link
EP (3) EP3088514B1 (enExample)
JP (2) JP5758920B2 (enExample)
KR (1) KR101928403B1 (enExample)
CN (1) CN102933707B (enExample)
AU (1) AU2011222452B2 (enExample)
BR (2) BR112012022029B1 (enExample)
CA (1) CA2791461C (enExample)
DK (1) DK2865751T3 (enExample)
ES (2) ES2606532T3 (enExample)
FI (1) FIC20230032I1 (enExample)
FR (1) FR23C1041I2 (enExample)
HR (1) HRP20200428T1 (enExample)
HU (2) HUE030959T2 (enExample)
IL (2) IL221741A (enExample)
IN (1) IN2012MN02262A (enExample)
NL (1) NL301249I2 (enExample)
NO (1) NO2023041I1 (enExample)
NZ (2) NZ602317A (enExample)
PL (1) PL2865751T3 (enExample)
SG (2) SG10201502609QA (enExample)
SI (1) SI2865751T1 (enExample)
WO (1) WO2011107990A1 (enExample)
ZA (1) ZA201206725B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
JP5758920B2 (ja) * 2010-03-02 2015-08-05 プロタリクス リミテッド 安定化α−ガラクトシダーゼおよびその使用
JP5913372B2 (ja) * 2011-01-20 2016-04-27 プロタリクス リミテッド 植物および植物細胞におけるα−ガラクトシダーゼの発現のための核酸発現構築物
TWI793159B (zh) * 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
KR102702200B1 (ko) 2014-12-22 2024-09-02 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
PL3271453T3 (pl) 2015-03-17 2022-01-17 eleva GmbH Glikozylowane białka lizosomowe, sposób wytwarzania i zastosowania
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
NZ755725A (en) * 2017-01-05 2023-06-30 Protalix Ltd Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase
US11517613B2 (en) * 2017-06-07 2022-12-06 Amano Enzyme Inc. Lactase bulk powder and lactase preparation
MX2021007552A (es) 2018-12-20 2021-08-11 Codexis Inc Variantes de alfa-galactosidasa humana.
AR121457A1 (es) * 2020-02-28 2022-06-08 Codexis Inc VARIANTES DE a-GALACTOSIDASA HUMANA
JP2023548496A (ja) 2020-11-03 2023-11-17 プロタリクス リミテッド 修飾ウリカーゼ及びその使用
CN112176026A (zh) * 2020-11-06 2021-01-05 诺道中科(北京)生物科技有限公司 一种α-半乳糖苷酶活性的检测试剂盒
CN116254287B (zh) * 2022-11-24 2024-06-04 西北农林科技大学 玉米ZmAGA3基因用于提高植物耐旱性的应用
CN118243646B (zh) * 2024-04-24 2025-01-24 武汉简为医疗科技有限公司 一种乳糖不耐受检测试剂盒及其使用方法
JP7745040B1 (ja) * 2024-06-21 2025-09-26 デンカ株式会社 目的タンパク質の回収方法及び製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (en) 1991-10-03 1993-04-04 Guy Ampleman Glycidyl azide polymer
US6329191B1 (en) * 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
DE69839563D1 (de) * 1997-09-05 2008-07-10 Altus Pharmaceuticals Inc Kohlenhydrat-vernetzte glykoproteinkristalle
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
DE60022336T2 (de) 1999-04-02 2006-06-22 Ajinomoto Co., Inc. Vefahren zur herstellung von peptiduntereinheiten aus polymer-proteinen
EP1523548B1 (en) 2002-05-15 2009-12-30 Agricultural Research Organization Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same
US7951557B2 (en) * 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
PL1877099T3 (pl) * 2005-04-06 2013-02-28 Genzyme Corp Terapeutyczne koniugaty zawierające enzym lizosomalny, kwas polisialowy i grupę kierującą
AU2006316122A1 (en) * 2005-11-18 2007-05-24 Altif Laboratories Inc. Novel highly functional enzyme having modified substrate-specificity
WO2008075957A1 (en) 2006-12-21 2008-06-26 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (en) * 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
CA2696699A1 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
JP5758920B2 (ja) * 2010-03-02 2015-08-05 プロタリクス リミテッド 安定化α−ガラクトシダーゼおよびその使用

Also Published As

Publication number Publication date
KR20130056216A (ko) 2013-05-29
IL253249A (en) 2019-08-29
EP3088514B1 (en) 2018-11-28
EP2865751A1 (en) 2015-04-29
CN102933707A (zh) 2013-02-13
HUE030959T2 (en) 2017-06-28
WO2011107990A1 (en) 2011-09-09
HRP20200428T1 (hr) 2020-06-12
RU2012141651A (ru) 2014-04-10
JP2014237694A (ja) 2014-12-18
CA2791461A1 (en) 2011-09-09
DK2865751T3 (en) 2017-01-09
BR112012022029B1 (pt) 2022-10-11
SG183558A1 (en) 2012-10-30
FR23C1041I2 (fr) 2024-08-02
IL253249B (en) 2020-08-31
HK1180720A1 (en) 2013-10-25
SG10201502609QA (en) 2015-05-28
EP2542675A1 (en) 2013-01-09
NL301249I1 (enExample) 2023-11-08
JP5871999B2 (ja) 2016-03-01
NZ623294A (en) 2015-10-30
EP3088514A1 (en) 2016-11-02
NZ602317A (en) 2014-04-30
NO2023041I1 (no) 2023-11-01
EP2865751B1 (en) 2016-09-14
NL301249I2 (nl) 2023-12-14
EP2542675B1 (en) 2014-12-17
FIC20230032I1 (fi) 2023-11-02
AU2011222452B2 (en) 2015-09-03
CN102933707B (zh) 2015-09-30
HUS2300038I1 (hu) 2023-11-28
ES2708843T3 (es) 2019-04-11
ES2606532T3 (es) 2017-03-24
PL2865751T3 (pl) 2017-03-31
RU2604795C2 (ru) 2016-12-10
KR101928403B1 (ko) 2018-12-14
ZA201206725B (en) 2013-06-26
JP2013520986A (ja) 2013-06-10
SI2865751T1 (sl) 2017-01-31
BR112012022029A2 (pt) 2021-05-18
JP5758920B2 (ja) 2015-08-05
BR122014021216A2 (pt) 2021-06-01
FR23C1041I1 (enExample) 2023-12-29
IN2012MN02262A (enExample) 2015-06-12
CA2791461C (en) 2019-10-22
AU2011222452A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
HUS2300038I1 (hu) Stabilizált alfa-galaktozidáz és ennek alkalmazásai
IL226904A (en) Inganol-3-acetylates iii and Inganol-3-carbamates
IL249669B (en) Converted 5-fluoro-h1-pyrazolopyridines and their use
LT2539326T (lt) Sujungti bisariliniai ariltriazolonai ir jų panaudojimas
GB201012175D0 (en) Procedure and mechanisms
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
IL230511A0 (en) 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
IL220939A0 (en) Compounds and methods
EP2523664A4 (en) COMPOUNDS AND METHODS
ZA201208173B (en) Peptices and their use
IL229844B (en) Anti-psgl-1 antibodies and their use
IL220812A0 (en) Compounds and methods
SI2531518T1 (sl) Oligopeptidne spojine in njihova uporaba
SI2605757T1 (sl) Formulacije na osnovi nalbufina in njihove uporabe
EP2523560A4 (en) CONNECTIONS AND METHODS
PL2547464T3 (pl) Układ i układ wentylacyjny
GB201001369D0 (en) Tri-flights and stems
GB2485537B8 (en) Integral - surface and air - personal transport
GB201001384D0 (en) Light-fitting and associated methods
GB201119443D0 (en) GoWinging Concept and patent
GB201014319D0 (en) Compounds and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed